Overlap syndromes among autoimmune liver diseases
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The three major immune disorders of the liver are autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Variant forms of these diseases are generally called overlap syndromes, although there has been no standardised definition. Patients with overlap syndromes present with both hepatitic and cholestatic serum liver tests and have histological features of AIH and PBC or PSC. The AIH-PBC overlap syndrome is the most common form, affecting almost 10% of adults with AIH or PBC. Single cases of AIH and autoimmune cholangitis (AMA-negative PBC) overlap syndrome have also been reported. The AIH-PSC overlap syndrome is predominantly found in children, adolescents and young adults with AIH or PSC. Interestingly, transitions from one autoimmune to another have also been reported in a minority of patients, especially transitions from PBC to AIH-PBC overlap syndrome. Overlap syndromes show a progressive course towards liver cirrhosis and liver failure without treatment. Therapy for overlap syndromes is empiric, since controlled trials are not available in these rare disorders. Anticholestatic therapy with ursodeoxycholic acid is usually combined with immunosuppressive therapy with corticosteroids and/or azathioprine in both AIH-PBC and AIH-PSC overlap syndromes. In end-stage disease, liver transplantation is the treatment of choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746 · cited 7×
“. However, this conclusion is somewhat controversial, since the treatment was not standardized and no difference was found when the diagnostic criteria proposed by Chazouilleres et al [ 5 ]”
BackgroundMethodResultInfluentialGregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448 · cited 1×
“histological features, prognostic surrogate markers, and development of colonic dysplasia associated with accompanying ulcerative colitis, although long-term efficacy of UDCA still remains unproven [ 48-52 ]”
BackgroundSelf-citationEpidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Lohse, A. W., zum Büschenfelde, K.-H. M., Franz, B., Kanzler, S., Gerken, G., & Dienes, H.-P. (1999) · Hepatology · doi:10.1002/hep.510290409 · Cited by 278
Prince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261 · cited 1×
“Although elevated serum IgM is characteristic for patients with PBC, it is not regarded mandatory to establish the diagnosis [ 12 ,13]”
BackgroundClinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Joshi, S., Cauch-Dudek, K., Wanless, I. R., Lindor, K. D., Jorgensen, R., Batts, K., & Heathcote, J. E. (2002) · Hepatology · doi:10.1053/jhep.2002.30902 · Cited by 174 · cited 1×
“In a strictly defined cohort of 16 patients with AIH-PBC overlap syndrome, the response to UDCA therapy (13-15 mg/kg daily) and the survival of the patients were similar to patients with classical PBC [ 31 ]”
ResultDevelopment of autoimmune hepatitis in patients with typical primary biliary cirrhosis
Poupon, R., Chazouilleres, O., Corpechot, C., & Chrétien, Y. (2006) · Hepatology · doi:10.1002/hep.21229 · Cited by 170 · cited 3×
“. A well-defined series of 12 patients with PBC followed by AIH was described in 282 PBC patients [ 29 ]”
BackgroundInfluentialOverlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes
Silveira, M. G., Talwalkar, J. A., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01136.x · Cited by 165
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisNote
van Buuren, H. R., van Hoogstraten, H. J. F., Terkivatan, T., Schalm, S. W., & Vleggaar, F. P. (2000) · Journal of Hepatology · doi:10.1034/j.1600-0641.2000.033004543.x · Cited by 143
Cullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136 · cited 1×
“at higher doses (> 20 mg/kg daily) may be superior to standard doses for patients with PSC [ 53 ]”
BackgroundSelf-citationColombato, L. A., Alvarez, F., Côté, J., & Huet, P.-M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90829-x · Cited by 104
Autoimmune hepatitis and its variant syndromes
BEN-ARI, Z., & CZAJA, A. J. (2001) · Gut · doi:10.1136/gut.49.4.589 · Cited by 102
Kanzler, S., Bozkurt, S., Herkel, J., Galle, P., Dienes, H., & Lohse, A. (2001) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2001-12906 · Cited by 33
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Precise prevalence of PBC–AIH overlap syndrome is unknown but approximately 10% of adults with AIH or PBC may belong in this overlap category [67–69].”
BackgroundDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
“It was stated that these ‘‘variants’’ should always be considered once PBC has been diagnosed and the patient responds poorly to ursodeoxycholic acid (UDCA) because of potential therapeutic implications (i.e. the need of immunosuppression) [60].”
BackgroundBoberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555
“These conditions may be difficult to classify and are commonly designated as ‘‘overlap syndromes’’ [1–5].”
BackgroundEpidemiology and clinical characteristics of autoimmune hepatitis in The Netherlands
van Gerven, N. M. F., Verwer, B. J., Witte, B. I., van Erpecum, K. J., van Buuren, H. R., Maijers, I., Visscher, A. P., Verschuren, E. C., van Hoek, B., Coenraad, M. J., et al. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.946083 · Cited by 164
Self-citation
Metadata
- Authors
- Rust, C., & Beuers, U.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2008
- Volume
- 14
- Issue
- 21
- Pages
- 3368
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2065665184
- Cited by
- 158
- References
- 18
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.